Feb 16, 2024 / 07:30AM GMT
Magnus Tolleshaug - Vistin Pharma ASA - COO
Welcome everyone to this Q4 and preliminary 2023 results presentation of Vistin Pharma. This presentation will be held by myself, Magnus Tolleshaug, the CEO of the company; and also Alexander Karlsen, our CFO of the company.
I will now go through the financial highlights. We are happy to announce that Vistin Pharma has had another strong quarter. The revenue of the fourth quarter ended at NOK111 million versus NOK99 million in Q4 2022, which represents a 12% increase. The increased volume from the new production line compared to the same quarter last year has resulted in more volumes available for sale. The 2023 revenue ended at a record high NOK438 million compared to NOK305 million last year. So a 44% increase.
The strong revenue increase in 2023 reflects a year with the two production lines running. Although the new line is still in the ramp-up phase. The EBITDA of the fourth quarter ended at NOK25 million versus NOK10 million in the fourth quarter of 2022. The EBITDA was positively affected by increased sales volume, a stronger euro versus
Q4 2023 Vistin Pharma ASA Earnings Call Transcript
Feb 16, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers